National survey of anemia prevalence after kidney transplantation in Argentina.
Anemia is prevalent in kidney transplant recipients and likely contributes to morbidity and mortality. The definition of anemia as established by the World Health Organization and subsequently adopted by the American Society of Transplantation is a hemoglobin concentration of 12 g/dL or less in women and 13 g/dL or less in men. Using this definition, the prevalence of anemia is nearly 30%. The National Survey of Post Transplant Anemia (PTA) in kidney transplant recipients in Argentina was conducted to evaluate the incidence of PTA at 1 year and its relationship to variables that influence transplantation outcome. At 1 year posttransplantation, mean (SD) hemoglobin concentration was 12.43 (1.77) g/dL (n = 379), hematocrit concentration was 38.26% (5.59%) (n = 379), serum creatinine concentration was 1.51 (0.72) mg/dL (n = 380), and creatinine clearance was 60.8 (22.47) mL/min (n = 334). The prevalence of PTA in Argentina at 1 year posttransplantation was 42.25%. At univariate analysis, female sex, immunosuppression regimen (mycophenolate mofetil plus mammalian target of rapamycin), and pediatric age group were associated with anemia. At multivariate analysis, only renal function and pediatric age group were associated with anemia. The mean hemoglobin level at year of transplant was 12.43 g/dL +/-1.77 and the prevalence of PTA in Argentina at year of transplant is 42.25%. Results of our survey show a correlation between Hb levels and graft function and pediatric recipient.
Petrone
H
H
Unidad de Trasplante Renal CRAI SUR CUCAIBA, La Plata, Argentina. petronehugo@gmail.com
Arriola
M
M
Re
L
L
Taylor
F
F
Bruzzone
M
M
Chiurchu
C
C
Schiavelli
R
R
D000328:Adult; D000740:Anemia / Q000097:blood / Q000453:epidemiology* / Q000209:etiology; D001118:Argentina; D002102:Cadaver; D002648:Child; D003404:Creatinine / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D006306:Health Surveys; D006400:Hematocrit; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000276:immunology; D019520:Living Donors; D008297:Male; D011183:Postoperative Complications / Q000453:epidemiology / Q000209:etiology; D014019:Tissue Donors
D006454:Hemoglobins; D007166:Immunosuppressive Agents; D003404:Creatinine